Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04185272 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Butyrophilins Role in Colon Cancer

Study acronym: IMMUNOCOL
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 13 words
  2. Study site revisedv7
  3. Primary completion date: Jun 30, 2025 to Jun 30, 2027v6
  4. Primary completion date: Jun 2023 to Jun 30, 2025v5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date changed from estimate of Feb 2020 to Jun 30, 2020
    • Study sites: 0 to 1
    • Primary completion date: Feb 2023 to Jun 2023
    • Study completion date: Feb 2028 to Jun 2028
  2. Primary endpoint revisedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer
Trial Details
NCT Number NCT04185272
Lead Sponsor Institut Paoli-Calmettes
Conditions
(from sponsor)		 Colonic Cancer
Related terms Colonic Neoplasms
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov